Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective
Crossref DOI link: https://doi.org/10.1186/S12913-015-1139-Y
Published Online: 2015-11-05
Published Print: 2015-06
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Charokopou, M.
McEwan, P.
Lister, S.
Callan, L.
Bergenheim, K.
Tolley, K.
Postema, R.
Townsend, R.
Roudaut, M.
License valid from 2015-06-01